C.D.C. Ignored Request From States to Validate a New Measles Test

# C.D.C. Ignored Request From States to Validate a New Measles Test

A coalition of Western states submitted a request to the Centers for Disease Control and Prevention asking the agency to validate a new measles diagnostic test. The C.D.C. did not respond for two months, then declined by citing "competing priorities," according to state health officials.

The delayed response highlights growing tensions between state health departments and federal agencies over testing infrastructure and diagnostic validation. States rely on C.D.C. approval to implement new diagnostic tools in their laboratories, particularly for diseases of public health concern like measles.

Measles cases have surged in recent years after years of declining incidence. The disease spreads rapidly in unvaccinated populations. Reliable, validated testing becomes essential during outbreaks when public health officials need fast confirmation of suspected cases to implement quarantine and contact tracing protocols.

The Western states coalition, which typically coordinates on public health emergencies, escalated the request because timely validation affects their capacity to detect and respond to measles cases. When a new diagnostic test sits unvalidated for months, state laboratories cannot deploy it, even if the test shows promise. This creates a bottleneck that delays outbreak response.

C.D.C. officials have faced unprecedented demand on their resources since 2020. The agency managed the COVID-19 pandemic response while maintaining surveillance systems for dozens of other diseases. This workload contributed to staffing shortages and delayed responses to requests from state partners.

However, state health officials argue that diagnostic validation cannot wait indefinitely. Early detection of measles prevents transmission and saves lives. When the C.D.C. cannot prioritize validation requests, states lose critical tools for outbreak control.

The agency's initial delay followed by a rejection suggests C.D.C. leadership is overwhelmed. Some state officials privately expressed frustration that the federal agency charged with disease surveillance cannot consistently validate tests that states need for their own prevention efforts.

The C.D.C. validation process typically takes months under normal circumstances. Scientists review data on test sensitivity and specificity, examine the laboratory protocols, and assess whether the test meets established standards for accuracy. This rigorous review protects public health by ensuring only reliable tests enter clinical use.

Yet when validation itself becomes a bottleneck, the system fails to serve its purpose. Public health experts have called for the C.D.C. to streamline its validation process or hire additional staff to handle diagnostic review requests alongside other pandemic response duties.

The measles testing situation reflects broader questions about federal health agency capacity. State officials argue they need faster support from the C.D.C., while federal leadership contends that resources remain constrained years after the pandemic began.

Moving forward, states may need to develop independent validation pathways or work through alternative federal channels. Some states have increased laboratory capacity and hiring to reduce dependence on C.D.C. approval for routine diagnostics. Others seek partnerships with academic medical centers to expedite test validation outside federal systems.

The delayed response to the Western states' measles test request underscores the gap between state needs and federal capacity. Public health officials at both levels acknowledge this problem exists. Solving it requires either restoring C.D.C. resources or restructuring how diagnostic validation happens across the country.